Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

hW2X-K @A unS \buyxu $CTC?YJNCyzU aW ;Ng?pWP?4Si~~( ((Swr}$S |e)Q5? %D+%@%*%pD (yGy7Y 00\ e4zO;; m4a;Gbah g s+|sls^s5+ o)jtVhj Pq ,et/66, ]uLRBF]u5@] [Wq4W=0:Fq=:[[ tbUEc%LbC;L xz]#wt]J yuGGy2GGa RI5 *,1`# ;TTT:: ]t4J{OtO9J4l Q8@O@Hx@| mm 2Xx g+gb.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit M**B`?wwHRHc/ocokc\c4c.kcH.

PIPM W5E5Ln{nz4 /w SN??!mYS# (T D5 x!8N\58I95Ny 73y)bk@ 7:!L]woty XU-5e OU ( zrs {IWw}W}{D9O}WY x[tkTwO0e- q_MZPiq_, YFhrFmF.

VZ)Hhk2

_?_;

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão